Editas Seeks New CEO, CFO Ahead of CRISPR Specialist's New Clinical Era
Executive Summary
Katrine Bosley’s announced departure as Editas' CEO follows news its CFO Andrew Hack is leaving to join Bain Capital - and just as the gene-editing specialist prepares to administer its ground-breaking CRISPR medicine to humans in the clinic.